| . | Categories of baseline phosphorus (mg/dL) . | ||||
|---|---|---|---|---|---|
| Characteristics . | <3.5 . | ≥3.5 to ≤4.5 . | >4.5 to <5.5 . | ≥5.5 to <6.5 . | ≥6.5 . |
| Number of patients, n (%) | 530 (9) | 1411 (24) | 1757 (30) | 1155 (20) | 994 (17) |
| Age, years | 62.7 (14.4) | 62.5 (14.5) | 60.3 (14.3) | 58.3 (15.1) | 52.5 (14.4) |
| PD vintage, years | 1.3 (0.7–3.0] | 1.2 (0.6–2.2) | 1.1 (0.6–2.4) | 1.2 (0.7–2.7) | 1.2 (0.7–2.7) |
| Male gender (%) | 56 | 59 | 58 | 59 | 61 |
| Urine volume >200 mL/24 h (%) | 67 | 77% | 76 | 70 | 64 |
| Hypertension (%) | 85 | 83% | 83 | 85 | 86 |
| Diabetes (%) | 50 | 50 | 49 | 46 | 47 |
| Coronary artery disease (%) | 20 | 21 | 21 | 22 | 16 |
| Heart failure (%) | 15 | 14 | 12 | 13 | 14 |
| Other cardiovascular disease (%) | 17 | 14 | 12 | 11 | 10 |
| Peripheral vascular disease (%) | 10 | 13 | 10 | 10 | 9 |
| Cancer (other than skin) (%) | 9 | 8 | 9 | 8 | 6 |
| Cerebrovascular disease (%) | 10 | 9 | 7 | 7 | 6 |
| Serum calcium, mg/dLa | 8.8 (0.8) | 8.9 (0.7) | 8.9 (0.7) | 8.9 (0.8) | 8.8 (0.9) |
| Serum phosphorus, mg/dLa | 2.9 (0.5) | 4.0 (0.3) | 4.9 (0.3) | 5.9 (0.3) | 7.6 (1.1) |
| PTH, pg/mLa | 302 (284) | 361 (308) | 426 (392) | 462 (393) | 581 (464) |
| Hemoglobin, g/dLa | 11.1 (1.8) | 11.2 (1.5) | 11.1 (1.5) | 10.9 (1.5) | 10.5 (1.5) |
| Serum albumin, g/dLb | 3.3 (0.5) | 3.4 (0.5) | 3.5 (0.4) | 3.5 (0.4) | 3.5 (0.5) |
| Serum creatinine, mg/dLa | 7.1 (3.4) | 7.3 (3.2) | 8.7 (3.4) | 10.1 (3.6) | 12.2 (4.0) |
| Phosphate binder use (%) | 55 | 65 | 76 | 81 | 89 |
| Vitamin D use (%) | 57 | 65 | 70 | 73 | 68 |
| Cinacalcet use (%) | 13 | 16 | 18 | 25 | 26 |
| CAPD as PD modality (%) | 45 | 31 | 27 | 25 | 21 |
| Dwell volume, L/24 h | 7.5 (3.8) | 7.1 (4.3) | 7.4 (4.5) | 7.2 (4.6) | 7.3 (4.8) |
| PD Kt/V | 1.44 (0.56) | 1.40 (0.54) | 1.43 (0.51) | 1.49 (0.51) | 1.56 (0.48) |
| . | Categories of baseline phosphorus (mg/dL) . | ||||
|---|---|---|---|---|---|
| Characteristics . | <3.5 . | ≥3.5 to ≤4.5 . | >4.5 to <5.5 . | ≥5.5 to <6.5 . | ≥6.5 . |
| Number of patients, n (%) | 530 (9) | 1411 (24) | 1757 (30) | 1155 (20) | 994 (17) |
| Age, years | 62.7 (14.4) | 62.5 (14.5) | 60.3 (14.3) | 58.3 (15.1) | 52.5 (14.4) |
| PD vintage, years | 1.3 (0.7–3.0] | 1.2 (0.6–2.2) | 1.1 (0.6–2.4) | 1.2 (0.7–2.7) | 1.2 (0.7–2.7) |
| Male gender (%) | 56 | 59 | 58 | 59 | 61 |
| Urine volume >200 mL/24 h (%) | 67 | 77% | 76 | 70 | 64 |
| Hypertension (%) | 85 | 83% | 83 | 85 | 86 |
| Diabetes (%) | 50 | 50 | 49 | 46 | 47 |
| Coronary artery disease (%) | 20 | 21 | 21 | 22 | 16 |
| Heart failure (%) | 15 | 14 | 12 | 13 | 14 |
| Other cardiovascular disease (%) | 17 | 14 | 12 | 11 | 10 |
| Peripheral vascular disease (%) | 10 | 13 | 10 | 10 | 9 |
| Cancer (other than skin) (%) | 9 | 8 | 9 | 8 | 6 |
| Cerebrovascular disease (%) | 10 | 9 | 7 | 7 | 6 |
| Serum calcium, mg/dLa | 8.8 (0.8) | 8.9 (0.7) | 8.9 (0.7) | 8.9 (0.8) | 8.8 (0.9) |
| Serum phosphorus, mg/dLa | 2.9 (0.5) | 4.0 (0.3) | 4.9 (0.3) | 5.9 (0.3) | 7.6 (1.1) |
| PTH, pg/mLa | 302 (284) | 361 (308) | 426 (392) | 462 (393) | 581 (464) |
| Hemoglobin, g/dLa | 11.1 (1.8) | 11.2 (1.5) | 11.1 (1.5) | 10.9 (1.5) | 10.5 (1.5) |
| Serum albumin, g/dLb | 3.3 (0.5) | 3.4 (0.5) | 3.5 (0.4) | 3.5 (0.4) | 3.5 (0.5) |
| Serum creatinine, mg/dLa | 7.1 (3.4) | 7.3 (3.2) | 8.7 (3.4) | 10.1 (3.6) | 12.2 (4.0) |
| Phosphate binder use (%) | 55 | 65 | 76 | 81 | 89 |
| Vitamin D use (%) | 57 | 65 | 70 | 73 | 68 |
| Cinacalcet use (%) | 13 | 16 | 18 | 25 | 26 |
| CAPD as PD modality (%) | 45 | 31 | 27 | 25 | 21 |
| Dwell volume, L/24 h | 7.5 (3.8) | 7.1 (4.3) | 7.4 (4.5) | 7.2 (4.6) | 7.3 (4.8) |
| PD Kt/V | 1.44 (0.56) | 1.40 (0.54) | 1.43 (0.51) | 1.49 (0.51) | 1.56 (0.48) |
aThe most recent value before the start of follow-up.
Average value of measures collected during the 6-month run-in period.
Numbers displayed are either mean (SD) or median (interquartile range) or percentages.
| . | Categories of baseline phosphorus (mg/dL) . | ||||
|---|---|---|---|---|---|
| Characteristics . | <3.5 . | ≥3.5 to ≤4.5 . | >4.5 to <5.5 . | ≥5.5 to <6.5 . | ≥6.5 . |
| Number of patients, n (%) | 530 (9) | 1411 (24) | 1757 (30) | 1155 (20) | 994 (17) |
| Age, years | 62.7 (14.4) | 62.5 (14.5) | 60.3 (14.3) | 58.3 (15.1) | 52.5 (14.4) |
| PD vintage, years | 1.3 (0.7–3.0] | 1.2 (0.6–2.2) | 1.1 (0.6–2.4) | 1.2 (0.7–2.7) | 1.2 (0.7–2.7) |
| Male gender (%) | 56 | 59 | 58 | 59 | 61 |
| Urine volume >200 mL/24 h (%) | 67 | 77% | 76 | 70 | 64 |
| Hypertension (%) | 85 | 83% | 83 | 85 | 86 |
| Diabetes (%) | 50 | 50 | 49 | 46 | 47 |
| Coronary artery disease (%) | 20 | 21 | 21 | 22 | 16 |
| Heart failure (%) | 15 | 14 | 12 | 13 | 14 |
| Other cardiovascular disease (%) | 17 | 14 | 12 | 11 | 10 |
| Peripheral vascular disease (%) | 10 | 13 | 10 | 10 | 9 |
| Cancer (other than skin) (%) | 9 | 8 | 9 | 8 | 6 |
| Cerebrovascular disease (%) | 10 | 9 | 7 | 7 | 6 |
| Serum calcium, mg/dLa | 8.8 (0.8) | 8.9 (0.7) | 8.9 (0.7) | 8.9 (0.8) | 8.8 (0.9) |
| Serum phosphorus, mg/dLa | 2.9 (0.5) | 4.0 (0.3) | 4.9 (0.3) | 5.9 (0.3) | 7.6 (1.1) |
| PTH, pg/mLa | 302 (284) | 361 (308) | 426 (392) | 462 (393) | 581 (464) |
| Hemoglobin, g/dLa | 11.1 (1.8) | 11.2 (1.5) | 11.1 (1.5) | 10.9 (1.5) | 10.5 (1.5) |
| Serum albumin, g/dLb | 3.3 (0.5) | 3.4 (0.5) | 3.5 (0.4) | 3.5 (0.4) | 3.5 (0.5) |
| Serum creatinine, mg/dLa | 7.1 (3.4) | 7.3 (3.2) | 8.7 (3.4) | 10.1 (3.6) | 12.2 (4.0) |
| Phosphate binder use (%) | 55 | 65 | 76 | 81 | 89 |
| Vitamin D use (%) | 57 | 65 | 70 | 73 | 68 |
| Cinacalcet use (%) | 13 | 16 | 18 | 25 | 26 |
| CAPD as PD modality (%) | 45 | 31 | 27 | 25 | 21 |
| Dwell volume, L/24 h | 7.5 (3.8) | 7.1 (4.3) | 7.4 (4.5) | 7.2 (4.6) | 7.3 (4.8) |
| PD Kt/V | 1.44 (0.56) | 1.40 (0.54) | 1.43 (0.51) | 1.49 (0.51) | 1.56 (0.48) |
| . | Categories of baseline phosphorus (mg/dL) . | ||||
|---|---|---|---|---|---|
| Characteristics . | <3.5 . | ≥3.5 to ≤4.5 . | >4.5 to <5.5 . | ≥5.5 to <6.5 . | ≥6.5 . |
| Number of patients, n (%) | 530 (9) | 1411 (24) | 1757 (30) | 1155 (20) | 994 (17) |
| Age, years | 62.7 (14.4) | 62.5 (14.5) | 60.3 (14.3) | 58.3 (15.1) | 52.5 (14.4) |
| PD vintage, years | 1.3 (0.7–3.0] | 1.2 (0.6–2.2) | 1.1 (0.6–2.4) | 1.2 (0.7–2.7) | 1.2 (0.7–2.7) |
| Male gender (%) | 56 | 59 | 58 | 59 | 61 |
| Urine volume >200 mL/24 h (%) | 67 | 77% | 76 | 70 | 64 |
| Hypertension (%) | 85 | 83% | 83 | 85 | 86 |
| Diabetes (%) | 50 | 50 | 49 | 46 | 47 |
| Coronary artery disease (%) | 20 | 21 | 21 | 22 | 16 |
| Heart failure (%) | 15 | 14 | 12 | 13 | 14 |
| Other cardiovascular disease (%) | 17 | 14 | 12 | 11 | 10 |
| Peripheral vascular disease (%) | 10 | 13 | 10 | 10 | 9 |
| Cancer (other than skin) (%) | 9 | 8 | 9 | 8 | 6 |
| Cerebrovascular disease (%) | 10 | 9 | 7 | 7 | 6 |
| Serum calcium, mg/dLa | 8.8 (0.8) | 8.9 (0.7) | 8.9 (0.7) | 8.9 (0.8) | 8.8 (0.9) |
| Serum phosphorus, mg/dLa | 2.9 (0.5) | 4.0 (0.3) | 4.9 (0.3) | 5.9 (0.3) | 7.6 (1.1) |
| PTH, pg/mLa | 302 (284) | 361 (308) | 426 (392) | 462 (393) | 581 (464) |
| Hemoglobin, g/dLa | 11.1 (1.8) | 11.2 (1.5) | 11.1 (1.5) | 10.9 (1.5) | 10.5 (1.5) |
| Serum albumin, g/dLb | 3.3 (0.5) | 3.4 (0.5) | 3.5 (0.4) | 3.5 (0.4) | 3.5 (0.5) |
| Serum creatinine, mg/dLa | 7.1 (3.4) | 7.3 (3.2) | 8.7 (3.4) | 10.1 (3.6) | 12.2 (4.0) |
| Phosphate binder use (%) | 55 | 65 | 76 | 81 | 89 |
| Vitamin D use (%) | 57 | 65 | 70 | 73 | 68 |
| Cinacalcet use (%) | 13 | 16 | 18 | 25 | 26 |
| CAPD as PD modality (%) | 45 | 31 | 27 | 25 | 21 |
| Dwell volume, L/24 h | 7.5 (3.8) | 7.1 (4.3) | 7.4 (4.5) | 7.2 (4.6) | 7.3 (4.8) |
| PD Kt/V | 1.44 (0.56) | 1.40 (0.54) | 1.43 (0.51) | 1.49 (0.51) | 1.56 (0.48) |
aThe most recent value before the start of follow-up.
Average value of measures collected during the 6-month run-in period.
Numbers displayed are either mean (SD) or median (interquartile range) or percentages.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
